521 results on '"Bamias, Giorgos"'
Search Results
2. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
3. Experimental Intestinal Stenosis Alters Crohn’s Disease-Like Intestinal Inflammation in Ileitis-Prone Mice
4. Specific Neuropeptide Expression in Crohn’s Disease Ileocolonic Resection Specimens Is Not Associated with Plexitis at the Ileal Margin or Postoperative Recurrence
5. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
6. Intestinal Stromal Cells in the Turmoil of Inflammation and Defective Connective Tissue Remodeling in Inflammatory Bowel Disease.
7. GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis
8. Candida tropicalis Infection Modulates the Gut Microbiome and Confers Enhanced Susceptibility to Colitis in Mice
9. Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study
10. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis
11. Exploring the Early Phase of Crohn’s Disease
12. Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts
13. An integrin αEβ7-dependent mechanism of IgA transcytosis requires direct plasma cell contact with intestinal epithelium
14. Neutralization of IL-1α ameliorates Crohn’s disease-like ileitis by functional alterations of the gut microbiome
15. Colonic mucosa barrier defects in collagenous and ischemic colitis
16. Landscape of Interactions between Stromal and Myeloid Cells in Ileal Crohn's Disease; Indications of an Important Role for Fibroblast-Derived CCL-2.
17. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease
18. GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis
19. Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study
20. Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study
21. The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD
22. Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach.
23. Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota
24. TNF-α Neutralization Ameliorates the Severity of Murine Crohn's-like Ileitis by Abrogation of Intestinal Epithelial Cell Apoptosis
25. Crohn's disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells
26. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF
27. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease.
28. The Greek Response to COVID-19: A True Success Story from an IBD Perspective
29. At the Junction of Immunity and Barrier Function: The Immunomodulatory Protein TL1A May Also Regulate Intestinal Permeability
30. Data from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
31. Figure S1, Figure S2, Table S1 from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
32. The Underappreciated Role of Secretory IgA in IBD
33. IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis
34. Pathway-based approaches to the treatment of inflammatory bowel disease
35. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?
36. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
37. Contributors
38. Recruitment of Inflammatory and Immune Cells in the Gut
39. Co-expression of fibrotic genes in inflammatory bowel disease; A localized event?
40. Assessment of Dietary Adequacy and Quality in a Sample of Patients with Crohn’s Disease
41. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
42. New Paradigms in the Pathogenesis of IBD
43. Amniotic Fluid-Derived Mesenchymal Stem/Stromal Cell-Derived Secretome and Exosomes Improve Inflammation in Human Intestinal Subepithelial Myofibroblasts
44. Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD
45. Cellular and Molecular Mediators of Intestinal Fibrosis
46. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis
47. Histological diversity of anti-PD1-induced colitis
48. Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine
49. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation
50. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.